AR065786A1 - Derivados de pirimidinas condensadas con heterociclos,procedimiento de preparacion,medicamentos que las contienen y usos como inhibidores de proteinas motoras mitoticas,en el tratamiento del cancer. - Google Patents
Derivados de pirimidinas condensadas con heterociclos,procedimiento de preparacion,medicamentos que las contienen y usos como inhibidores de proteinas motoras mitoticas,en el tratamiento del cancer.Info
- Publication number
- AR065786A1 AR065786A1 ARP080101127A ARP080101127A AR065786A1 AR 065786 A1 AR065786 A1 AR 065786A1 AR P080101127 A ARP080101127 A AR P080101127A AR P080101127 A ARP080101127 A AR P080101127A AR 065786 A1 AR065786 A1 AR 065786A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- derivatives
- contain
- pnr2
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos caracterizados por la formula (1) en donde E es un resto del grupo de formulas (2); X es O, NR o S; R1, R2 son, de modo independiente entre sí, H, A, Hal, SA, (CH2)pCN, SCN, (CF2)pCF3, SF5, OA, O(CF2)pCF3, S(CF2)pCF3, NR2, NRCOR, NRSO2R, NR(CH2)pNR2, ONR(CH2)pNR2, SO2NR(CH2)pNR2, CONR2, SO2NR2, COOR; R3 es H, A; A es alquilo lineal o ramificado C1-10, cicloalquilo C3-7; R4 es arilo o heteroarilo sustituido o mono- o polisustituido con arilo o heteroarilo, que puede estar sustituido con Hal, NO2, CN, A, OR, OCOR, NR2, CF3, OCF3, OCH(CF3)2, Hal, NO2, CN, OR, A, -(CY2)n-OR, -OCOR, -(CY2)n-CO2R, -(CY2)n-CN o -(CY2)n-NR2; Y es H, A, Hal, OR; R es H, A, (CH2)pO(CH2)pR3, (CH2)pNA(CH2)pR3; W es CH2, C=O, C=S o un enlace simple; Q1 es NR, O, S o un enlace simple; Z es -SO2-, -SO-, CO, CS, un resto del grupo de formulas (3) o un enlace simple; Q2 es NR, S, O o un enlace simple; R5 es H, (CY2)pNR2, (CY2)pOR, (CY2)pSR, un resto de formula (4), -(CY2)pQ1COQ1R, (CY2)pCOOR y, siempre que Q2 sea un enlace simple, también Hal; Hal es F, Br o Cl; n es 1, 2, 3 o 4, m es 0, 1 o 2, p es 0, 1, 2, 3, 4, 5, 6, 7 u 8; y s es 0, 1 o 2; así como sus derivados, solvatos, tautomeros, sales y estereoisomeros, incluyendo sus mezclas en todas las proporciones, y medicamentos que los contienen para utilizar en el tratamiento de tumores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007013854A DE102007013854A1 (de) | 2007-03-20 | 2007-03-20 | Tetrahydrochinoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065786A1 true AR065786A1 (es) | 2009-07-01 |
Family
ID=39692561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101127A AR065786A1 (es) | 2007-03-20 | 2008-03-19 | Derivados de pirimidinas condensadas con heterociclos,procedimiento de preparacion,medicamentos que las contienen y usos como inhibidores de proteinas motoras mitoticas,en el tratamiento del cancer. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100076012A1 (es) |
| EP (1) | EP2121706A1 (es) |
| JP (1) | JP2010521505A (es) |
| KR (1) | KR20090130071A (es) |
| CN (1) | CN101636401A (es) |
| AR (1) | AR065786A1 (es) |
| AU (1) | AU2008228570A1 (es) |
| BR (1) | BRPI0808742A2 (es) |
| CA (1) | CA2681261A1 (es) |
| DE (1) | DE102007013854A1 (es) |
| EA (1) | EA200901180A1 (es) |
| IL (1) | IL200966A0 (es) |
| MX (1) | MX2009009917A (es) |
| WO (1) | WO2008113456A1 (es) |
| ZA (1) | ZA200907306B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011084439A1 (en) * | 2009-12-17 | 2011-07-14 | Sanofi | Tetrahydrocarboline derivatives as eg5 inhibitors |
| CN103328449A (zh) * | 2011-01-26 | 2013-09-25 | 霍夫曼-拉罗奇有限公司 | 新的四氢喹啉衍生物 |
| JP6521387B2 (ja) * | 2014-04-18 | 2019-05-29 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| AR103598A1 (es) | 2015-02-02 | 2017-05-24 | Forma Therapeutics Inc | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac |
| AU2016215432B2 (en) | 2015-02-02 | 2020-07-30 | Valo Early Discovery, Inc. | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors |
| US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3172104A (en) | 1960-06-27 | 1965-03-02 | Giannini Controls Corp | Measurement of hypersonic flight data |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US5428051A (en) | 1992-10-13 | 1995-06-27 | University Of North Carolina | Methods of combating pneumocystis carinii pneumonia and compounds useful therefor |
| US5521189A (en) | 1994-05-06 | 1996-05-28 | The University Of Nc At Ch | Methods of treating pneumocystis carinii pneumonia |
| US5602172A (en) | 1994-05-06 | 1997-02-11 | The University Of North Carolina At Chapel Hill | Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor |
| US5643935A (en) | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
| US5723495A (en) | 1995-11-16 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Benzamidoxime prodrugs as antipneumocystic agents |
| US6172104B1 (en) | 1998-08-20 | 2001-01-09 | The University Of North Carolina At Chapel Hill | Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof |
| DE69933890T2 (de) | 1998-09-17 | 2007-03-15 | University Of North Carolina At Chapel Hill | Antimykotische wirkung von dikationischen molekülen |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| WO2000061186A1 (en) | 1999-04-08 | 2000-10-19 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
| US6569853B1 (en) | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| US7250423B2 (en) | 2001-09-24 | 2007-07-31 | Chao-Jun Li | Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers |
| ATE507220T1 (de) | 2003-12-20 | 2011-05-15 | Merck Patent Gmbh | Tetrahydropyranochinolinderivate |
| DE102004031656A1 (de) * | 2004-06-30 | 2006-01-19 | Merck Patent Gmbh | Tetrahydrochinoline |
| DE102005027168A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Tetrahydrochinoline |
-
2007
- 2007-03-20 DE DE102007013854A patent/DE102007013854A1/de not_active Withdrawn
-
2008
- 2008-02-22 BR BRPI0808742-3A patent/BRPI0808742A2/pt not_active IP Right Cessation
- 2008-02-22 JP JP2009553939A patent/JP2010521505A/ja active Pending
- 2008-02-22 EA EA200901180A patent/EA200901180A1/ru unknown
- 2008-02-22 MX MX2009009917A patent/MX2009009917A/es unknown
- 2008-02-22 CA CA002681261A patent/CA2681261A1/en not_active Abandoned
- 2008-02-22 WO PCT/EP2008/001422 patent/WO2008113456A1/de active Application Filing
- 2008-02-22 EP EP08715973A patent/EP2121706A1/de not_active Withdrawn
- 2008-02-22 AU AU2008228570A patent/AU2008228570A1/en not_active Abandoned
- 2008-02-22 US US12/531,602 patent/US20100076012A1/en not_active Abandoned
- 2008-02-22 CN CN200880008933A patent/CN101636401A/zh active Pending
- 2008-02-22 KR KR1020097021813A patent/KR20090130071A/ko not_active Application Discontinuation
- 2008-03-19 AR ARP080101127A patent/AR065786A1/es unknown
-
2009
- 2009-09-15 IL IL200966A patent/IL200966A0/en unknown
- 2009-10-19 ZA ZA200907306A patent/ZA200907306B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008228570A1 (en) | 2008-09-25 |
| BRPI0808742A2 (pt) | 2014-08-12 |
| MX2009009917A (es) | 2009-10-19 |
| KR20090130071A (ko) | 2009-12-17 |
| ZA200907306B (en) | 2010-07-28 |
| CN101636401A (zh) | 2010-01-27 |
| JP2010521505A (ja) | 2010-06-24 |
| US20100076012A1 (en) | 2010-03-25 |
| EA200901180A1 (ru) | 2010-04-30 |
| CA2681261A1 (en) | 2008-09-25 |
| EP2121706A1 (de) | 2009-11-25 |
| WO2008113456A1 (de) | 2008-09-25 |
| IL200966A0 (en) | 2010-05-17 |
| DE102007013854A1 (de) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065786A1 (es) | Derivados de pirimidinas condensadas con heterociclos,procedimiento de preparacion,medicamentos que las contienen y usos como inhibidores de proteinas motoras mitoticas,en el tratamiento del cancer. | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR058205A1 (es) | 5-fenil-3,6-dihidro-2-oxo-6h-[1,3,4] tiadiazinas sustituidas | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR068659A1 (es) | Derivados de imidazol inhibidores de autotaxina | |
| AR082109A1 (es) | Derivados de bipiridilo | |
| CO6300865A2 (es) | Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| AR096235A1 (es) | Arilquinazolinas | |
| AR053569A1 (es) | Derivados de pirazol | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR070995A1 (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfe | |
| AR048974A1 (es) | Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas. | |
| AR054232A1 (es) | Derivados de piridina -2- carboxamida como antagonistas de mglur5 | |
| AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
| AR053994A1 (es) | Sulfonilpirrolidinas sustituidas procedimiento para su preparacion y su uso como medicamentos | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR055376A1 (es) | Derivados de 1-acildihidropirazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |